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Abstract Cancer develops via the progressive accumulation of somatic mutations,
which subvert the normal operation of the gene regulatory network of the cell.
However, little is known about the order inwhichmutations are acquired in successful
clones. A particular sequence of mutations may confer an early selective advantage
to a clone by increasing survival or proliferation, or lead to negative selection by
triggering cell death. The space of allowed sequences of mutations is therefore
constrained by the gene regulatory network. Here, we introduce a methodology for
the systematic exploration of the effect of every possible sequence of oncogenic
mutations in a cancer cell modelled as a qualitative network. Our method uses
attractor identification using binary decision diagrams and can be applied to both
synchronous and asynchronous systems.We demonstrate ourmethod using a recently
developedmodel of ER-negative breast cancer.We show that there are differing levels
of constraint in the order of mutations for different combinations of oncogenes, and
that the effects of ErbB2/HER2 over-expression depends on the preceding mutations.
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1 Introduction
Multicellular organisms, in particular long-lived ones such as mammals, must assure
the survival and procreation of the organism as a whole over the individual survival
of a single cell. As such, they have evolved robustmechanisms to control proliferation
and to detect and remove damaged or malfunctioning cells [12]. Consequently, no
single mutation is believed to suffice to elicit tumour formation, rather cells require
several key changes in order to escape these controls, out-compete healthy cells,
and adapt to the new environment that emerges as a tumour forms [34]. These
controls, and the different characteristics that are favoured at different stages of
tumour evolution, will restrict which mutations are selected for and observed at
different stages. This results in an optimal order in which mutations must be acquired
for some cancers to be successful, as observed in colorectal cancer [2] or pancreatic
ductal adenocarcinoma [52].
This evolution is not linear; while fitter sub-clones out-compete their neighbours
they do not necessarily dominate and many tumours become highly heterogeneous,
with competition [32] and cooperation [64] between clones. This poses a problem
for treatment, with the degree of heterogeneity being a predictor of poor prognosis
[44] and serving as a pool of possible adaptations to therapy. Heterogeneity therefore
leads to the rapid emergence of acquired resistance [8], particularly in the case of
targeted therapy [15].
Despite the heterogeneity of mature tumours, they largely originate from a sin-
gle cell, even in cases of strong environmental factors such as smoking, or where
there is a germline mutation that causes a predisposition [23, 61]. Testimony to the
efficiency of the body’s tumour surveillance mechanisms, this suggests that even
with heterogeneity there will be shared mutations, with early mutations likely to be
the most prevalent among tumour sub-clones [66]. As these are also likely to be
driver mutations, treatments targeting these may be more broadly effective against
the entire tumour [63]. Furthermore, existing treatment may preferentially affect
late, sub-clonal mutations. For example, Sun et al. [63] observe that in acute myeloid
leukaemia, cells carrying early mutations persist and may play a part in relapse,
with similar results from Ding et al. [24]. This suggests that targeting early, founder
mutations may help avoid this pool of early mutations and reduce rates of relapse.
Finally, which mutations occur early may constrain the future behaviour of a tumour,
as seen in studies of myeloproliferative neoplasms [49] and pancreatic cancer [59].
In order to take advantage of this commonality underlying tumour heterogeneity, we
must be able to understand the constraints on the acquisition of tumour-promoting
mutations as the tumour progresses. We can then predict which mutations are likely
to occur early in tumour development, and so are best for treatment or early detection.
Existing studies have tried to shed light on the temporal evolution of tumours
by comparing metastases to primary tumours [41, 55], analysing sequencing data
from primary tumours for genetic recombinations [33, 47, 67], comparing regions
within biopsies [69] and single-cell sequencing [29]. However, these studies either
rely on metastases occurring late in tumour development, which may not always
be the case [31], have very few time-points within tumour evolution, or must rely
State Space Exploration to Determine How Mutation Order is Constrained in Cancer 3
on reconstruction of a history that has been distorted by selective sweeps over the
history of the tumour. This, coupled with difficulty in obtaining biopsy data for
early, asymptomatic, stages of tumour evolution, makes identification of the early
behaviour of the tumour more difficult [62]. In this study, we present a method to
study how positive and negative selection influences the evolution of tumours, and
so determines the order of mutations, based on the gene regulatory network. This
builds upon a biological understanding of the gene regulatory network of the cell to
model the defining constraints on early tumour development and so better map out
this stage using in silico models.
Wemodel the gene regulatory network of the cell as a discrete qualitative network
[54]; an extension of Boolean networks in which each node can take a finite number
of values, corresponding to, for example, under-, normal and over-expression of a
gene. This is necessary to capture the complexity of the regulatory network. For
example, the c-myc oncogene elicits distinct responses at each of these levels [46].
This and similar phenomena cannot be captured in a Boolean framework. We can
then model the evolution of cancer in the cell by changing the behaviour of nodes
affected by mutation. Using a discrete system rather than a continuous mathematical
model allows us to explore the entire state space of the system, and give definitive
answers as to how the cell responds to each mutation acquired as the tumour evolves.
By assigning cellular phenotypes to nodes that integrate the activity of the rest of
the network, we are able to tie phenotypes to qualitative network attractors. We then
identify all such attractors under all possible combinations of mutations.
We use the open source BioModelAnalyzer tool (BMA2), which we extend with
support for attractor identification. Previously, BMA supported stability analysis [18]
and Linear Temporal Logic (LTL) model checking [17] for synchronous qualitative
networks. With our modifications it now supports full attractor analysis for both
synchronous and asynchronous qualitative networks. This expands BMA to non-
deterministic and non-stabilising systems such as development and stem cell fate
specification.
As a proof-of-concept, we apply this to a recently developed model of the gene
regulatory network of ER-negative breast cancer cells (currently in submission).
Breast cancer is the second most common cancer worldwide at 11.9% of cancer
diagnoses in 2012, and the cause of over 500,000 deaths per year around the world
[27]. There has been a decline in breast cancer mortality in the UK of around 30%
between the late 1980s and 2006 [4], likely as a result of a combination of the
introduction of screening [39] and tamoxifen therapy [9]. However, of the major
breast cancer sub-types, both basal and triple negative (TNBC) breast cancers are
frequently estrogen-negative (ER-) and so not treatable by tamoxifen. These sub-
types have higher mortality [60] and have fewer treatment options [38]. In order
to better understand the development of such tumours, and so improve treatment, a
better understanding of their evolution is required. We show that our new method
can be used to explore the evolution of breast cancer based on an understanding of
2 http://biomodelanalyzer.org/
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the underlying gene regulatory network, and suggest how this can be built upon and
applied to other cancers in the future.
2 Qualitative Networks
In this section we formally define qualitative networks, which are a framework for
modelling gene regulatory networks. In a qualitative network, we have a variable
for each gene or protein we wish to model. We also have variables that correspond
to overall cellular behaviour, such as proliferation and apoptosis, which integrate
the signals from the rest of the network. These give a read out of the effect on
the observable behaviours of the cell, the phenotype, due to its genetic regulatory
network being in a particular attractor. Each variable ranges over a finite range, such
as 0–2, and has a user-defined target function that defines how its value is influenced
by other genes. The system is updated over discrete time steps by following the logic
of the target functions and updating the values of each variable. We may update
variables using a synchronous or asynchronous update scheme.
A qualitative network (QN)[54], Q(V,T, N), of granularity N + 1 consists of
a set of variables: V = {v1, v2, . . . , vn}, together with a set of target functions:
T = {T1,T2, . . . ,Tn}. A state of the system is a finite map s : V → {0, 1, . . . , N}.
For each variable vi ∈ V we have target function Ti ∈ T associated with it:
Ti : {0, 1, . . . , N}n → {0, 1, . . . , N}. 3 Target functions direct the execution of the
network: given state s = (d1, d2, . . . , dn), the next value of variable vi is:
d ′i =

di + 1 di < Ti(s) and di < N,
di − 1 di > Ti(s) and di > 0,
di otherwise
(1)
We say that a target function Ti is enabled at state s if d ′i , di , i.e. the next value
of vi is not equal to its current value.
In a synchronous qualitative network all variables are updated at each time step
by firing all target functions using synchronous parallelism. That is, from state
s = (d1, d2, . . . , dn), the successor state is s′ = (d ′1, d
′
2, . . . , d
′
n). A synchronous
qualitative network has a deterministic dynamics – given an initial state, all future
states are uniquely determined.
In an asynchronous qualitative network, we instead update variables using asyn-
chronous parallelism. State s′ = (d1, d2, . . . , d ′i , . . . , dn) is a successor of state
s = (d1, d2, . . . , di, . . . , dn) if Ti is enabled. That is, we get to the next state s′,
by non-deterministically selecting an enabled target function Ti and updating the
value of the associated variable vi . If no target function is enabled, for convenience
we define the successor state to be s′ = s. That is, the system remains in its current,
stable, state, where it will remain.
3 For simplicity, here we assume that all variables have the same range {0, . . . , N }. Our imple-
mentation supports individual ranges for variables.
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A concrete example of a qualitative network is the breast cancer model used in the
case study of this paper. This qualitative network models the signal transduction net-
work of a single mammary cell, where inputs from the environment are represented
as special variables. Additionally, special variables like Proliferation represent the
phenotypic read-out of the model as a function of intracellular variables. In this
model, Beta-Catenin is represented as a variable which ranges from 0 (unexpressed)
to 2 (highly expressed), and with a target function 2 − GSK3_Axin_APC_CK1,
which represents how its abundance in the cell is controlled by degradation by the
GSK3-Axin-APC-CK1 complex. To model a mutation which leads to the constitu-
tive activation of Beta-Catenin we would modify its target function to the constant
2. To model a knock-out we would modify the target function to 0. By applying such
changes in target function to variables which represent genes observed to mutate in
breast cancer, we can model the transition from a healthy cell to a cancerous cell.
A QN defines a transition system T = (S, R), where S is the set of all (N + 1)n
possible states of the network and R ⊆ S × S is the (synchronous or asynchronous)
successor relation. Since a qualitative network has a finite number of possible states,
any execution eventually converges to either a fixpoint attractor or a cycle of states,
called a loop attractor. Formally, an attractor is a set of states A ⊆ S such that for all
s ∈ A, we have that F(s,T) = A, where F(s,T) is the set of states reachable from s
in T .
Attractors represent the long-term behaviour of the biological system. A quali-
tative network will have the same set of fixpoint attractors whether it is executed
synchronously or asynchronously, but the two different execution types lead to dif-
ferent types of loop attractors [30]. The two modes of execution also change whether
an attractor is reachable from a given initial state. The choice of whether to use
the synchronous or asynchronous semantics when building a model depends on the
characteristics of the biological system under consideration. For stochastic and non-
stabilising systems such as stem cell differentiation, different potential interleavings
of gene expression events may need to be explored, motivating the asynchronous
semantics. For systems that are expected to exhibit stability the simpler synchronous
semantics may be more appropriate, such as in the case of the development of breast
cancer presented in this paper. We discuss identification of attractors of qualitative
networks in the next section.
3 Identifying attractors in QNs using binary decision
diagrams
Garg et al.[30] introduce an algorithm for identifying attractors in synchronous and
asynchronous Boolean networks. From a high-level point of view, this algorithm
works by choosing an arbitrary state of the network, and from this point simulating
forward until the system falls into an attractor. This represents one possible long
term-behaviour of the model. All states that reach this attractor are then eliminated
by running all possible backwards executions from this point, doing so in an efficient
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manner by using a data structure called a binary decision diagram. This process is
repeated until all states are explored, and therefore all attractors are found. Here, we
review this algorithm and extend it to qualitative networks for the first time.





Fig. 1: In our approach to identifying at-
tractors of qualitative networks, we repre-
sent Boolean functions using binary deci-
sion diagrams. Above, a binary decision
diagram for the majority function over
three variables (x1∧ x2)∨ (x2∧ x3)∨ (x3∧
x1) is shown [40].
A Reduced Ordered Binary Decision
Diagram (ROBDD, or simply BDD) is
a rooted directed acyclic graph with one
or two terminal nodes of out-degree
zero labelled 0 and 1, and with all other
nodes having out-degree two and la-
belledwith a variable x [11, 40].ABDD
is ordered — variables always occur in
the same order along any path from root
to terminal, and reduced — the left and
right branches of a node cannot lead to
the same node, and there are no two
distinct nodes n and n′ with isomorphic
subgraphs.
A BDD is essentially a compressed
representation of the truth table of a
Boolean function, with each path to a
root node representing an evaluation of
the function. A left branch at a variable represents an assignment of 0 to that vari-
able, and a right branch represents an assignment of 1. The value of the function
evaluation is given by the terminal node that the path ends at. Given a fixed or-
dering for the variables of a function, there is one unique BDD representation for
that function. Given two BDDs, we can combine them using any combination of
Boolean operators (e.g., ∨, ∧, or ¬). An example BDD for the majority function
(x1 ∧ x2) ∨ (x2 ∧ x3) ∨ (x3 ∧ x1) is shown in Figure 1.
BDDs allow for the efficient representation and manipulation of sets of objects
and relations over sets of objects. In many practical cases a BDD representation
allows the symbolic exploration of combinatorial spaces that would be intractable
to represent and explore explicitly, although in the worst case a BDD still requires
exponential space to represent all the solutions to a function.
3.2 Attractor identification algorithm
The algorithmofGarg et al.works bymanipulating aBDD representing the successor
relation of the network and BDDs representing sets of states. Starting from an
arbitrary initial state s, the algorithm explores all states that are reachable from s,
and all states that can reach s, by iteratively applying the successor relation forwards










if fr ∧ ¬ br = false then
attractors← attractors ∪ {fr}
end if
















for loop ∈ syncLoops do
if isAsyncLoop(loop) then
sharedAttractors← sharedAttractors ∨ loop




br← br ∨ backwardReachableStates(transitionBDD_async, br)
asyncLoops← asyncLoops ∪ {allAttractors(transitionBDD_async, br)}
return fix, asyncLoops
end function
Fig. 2: Pseudocode for the attractor finding algorithm.
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and backwards. An attractor has been found if the forward reachable states are
contained in the backward reachable states. The explored states are removed from
the state space and the process is repeated from another arbitrary state, until the entire
state space has been explored. Our variant of this algorithm is shown in Figure 2.
Following [30], when analysing an asynchronous network, we first analyse the
corresponding simpler synchronous network, and retain any loop attractors that are
also valid attractors of the asynchronous system. As an optimisation to the original
algorithm of Garg et al., we find all fixpoint attractors in one step by intersecting the
(synchronous) successor relation with the identity function.
To represent a set of states of a qualitative network as a binary decision diagram
we use a binary encoding, introducing for each variable vi of granularity N in the
QN dlog2 Ne binary variables, and ruling out invalid bit combinations which result
when N is not a power of 2 (line 3 of the algorithm in Figure 2, and also in the
fixpoints computation).
To represent each target function, we build a generalised truth table by evaluating
the function at each possible combination of input values, and then encode this table
as a binary decision diagram. To constrain the ranges of variables that need to be
considered in order to build this table our implementation relies on the decreasing
reachability sets algorithm of [17]. For models that contain target functions with a
large number of input variables, encoding a symbolic representation of the function
would be more appropriate. We then encode the successor relation of a synchronous
or asynchronous network as a BDD following [30]. We implemented this algorithm
in C++ and incorporated it into the open source tool BMA4. We make an imple-
mentation of the methodology outlined in this paper available through the command
line interface of BMA and associated source code. However, in the future we plan
to extend access to the web-based tool initially as part of the Natural Language
Interface [1]5, and eventually tools in the GUI.
4 Exploring order of mutations
We wish to explore the effect of all possible combinations of mutations to a set
of oncogenic genes, in order to determine if particular sequences of consecutive
mutations are predicted to be more favourable to cancer progression than others.
We make the simplification of assuming mutations are independent events, and that
the system reaches an attractor between mutations. For example, if the cancer under
consideration has mutations A, B and C, we consider the qualitative network model
with all possible combinations of these three mutations (Figure 3). To model the
mutation of a gene, we modify the associated target function to be a constant value.
We describe this process more formally below.
4 https://github.com/Microsoft/BioModelAnalyzer
5 Development builds of this interface can be accessed as a chat-bot in Skype
(https://join.skype.com/bot/711331aa-e775-49be-b99d-6c42fc25f6d2) or Telegram
(https://telegram.me/BioModelAnalyzerBot)
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We can represent a particular set of mutations M to a subset of variables V ′ ⊆ V
in a QN Q(V,T, N) as a set of variable/value pairs:
M = {(vi, ni) | vi ∈ V ′} (2)
where each vi denotes a gene that is mutated, and ni ∈ {0, . . . , N} represents whether
the gene is knocked out to value 0 or is constitutively expressed at some value > 0.We
model all mutations asmaximally effective (either completely inhibiting or activating
a variable). Different mutations may have different degrees of effect, for example
point mutations at different locations within a gene may impair protein folding in
different ways, but as most of the variables in the network range from 0-2 there is
limited scope to explore this. However, a qualitative network model can incorporate
higher granularities, so this could be a future extension of the model, but here we
assume the most oncogenic mutation.
The modified QN given after application of these mutations is obtained by sub-
stituting the target function for each vi ∈ V ′ by a constant function, T ′i (s) = ni:
Q′(V, {T ′i | vi ∈ V
















Fig. 3: To explore the order of mutations
ABC, we apply them in all possible orders
by constructing a powerset as above.
To consider all possible sequences of
mutations leading to a set of observed
mutations M , we construct the power-
set 2M and analyse all modified mod-
els resulting from applying each set of
mutations m ∈ 2M , starting with the
healthy state in which no mutations are
applied other than to model the pres-
ence of growth factors. (Figure 3). We
compute the attractors for each of these
models, and can then construct plots vi-
sualising levels of variables judged to be
representative of the health of the cell,
such as those controlling proliferation or apoptosis.
Charting paths through these plots allows us to determine favourable and un-
favourable sequences of mutations. For example, in a model with two oncogenes A
and B, if applying mutations {A} and {A, B} both result in modified models with
high levels of proliferation and low levels of apoptosis, while applying mutation {B}
results in a modified model with a low level of proliferation and a high level of apop-
tosis, this implies that it is favourable for the cancer for gene A to be mutated before
gene B. When constructing these plots we consider only attractors that are reachable
from a parent node. For example, for the model with mutations {A, B}, we consider
only those attractors that are now reachable with the additional mutation, starting
from states in the attractors of the model with mutation {A}, or from states in the
attractors of the model with mutation {B}. This assumes that there is enough time to
reach an attractor betweenmutation events.We have written R scripts that implement
this methodology, available at https://github.com/JFisherLab/MutationOrder.
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Model Variables Mutations Synchronous time (s) Asynchronous time (s)
Lung cancer 46 4 16 275
AML 42 5 37 37
CML 54 6 28 28
Breast cancer 75 7 57 57
Fig. 4: We assessed the practically of our method by applying it to four qualitative
network cancer cell models, with differing numbers of variables and mutations.
Execution time is shown above.
5 Results
5.1 Benchmarks
To assess the practicality of our method, we applied it to four models of gene
regulatory networks involved in cancers of different types: a lung cancer model (un-
published), a model of acute myeloid leukemia [58], a model of chronic myeloid
leukemia [16], and a model of ER-negative breast cancer (in submission). These
results are shown in Figure 4. All computations were performed on a Windows 10
PC with an Intel Xeon E5 @ 3.70Ghz and 16GB of RAM.
Note that if the model has only fixpoint attractors (no loops) under a particular set
of mutations when considering the network synchronously, then there are the same
attractors in the asynchronous case. The breast cancer, AML and CML leukemia
models all have only fixpoint attractors and therefore there is no time difference
when running the algorithm for either case. The lung cancer model, on the other
hand, has a complex loop attractor and so different behaviour depending on whether
it is being analysed synchronously or asynchronously. This leads to the much longer
running time for the algorithm when executed in asynchronous mode.
5.2 Application to a model of ER-negative breast cancer
As a proof-of-concept application of our methodology, we turn to a recently de-
veloped synchronous qualitative network model of ER-negative breast cancer (in
submission). To find mutations known to lead to cancer, we use the mutational pro-
files of common breast cancer cell lines [35]. We focus on ER-negative cell lines
as the main driver genes are in our existing breast cancer model. The phenotypes
we consider are proliferation and apoptosis, so we do not include mutations that
affect parts of the genetic regulatory network not in the model, for example genes
involved in invasiveness and differentiation such as E-cadherin. These phenotypes
are represented in the model by their own variables representing proliferation and
apoptosis, which integrate signals from terminally downstream genes and proteins
in their respective pathways. For different attractors, these will have different levels
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of activity indicating the predicted behaviour of the cell. The change in the activity
in these variables is visualised for the different cell lines below.
5.2.1 SKBR3 demonstrates tightly constrained path to cancer
SKBR3, which is an ER-negative basal epithelial cell line [36], shows an example
in which the model predicts that the order of mutations can be strongly constrained
by apoptosis (Fig. 5b). There is only one path from the healthy state that minimises
apoptosis while the cancer acquires the mutations shown in the SKBR3 cell line.
Our method suggests that the level of apoptosis, due to the action of c-myc in the
network model, is sufficient to strongly constrain the order of mutations. c-myc is
a strong trigger of apoptosis, mainly via p53, perhaps as a fail-safe for its potent
proliferative effects [25]. This means that in our model acquisition of an oncogenic
c-mycmutation ismost beneficial dependent upon several earliermutations removing
these safeguards, and we predict this encourages late mutation. This is as observed
in breast cancer, where in many cases c-myc is amplified, but this appears to be
associated with the later stages of tumour progression [13, 19, 3, 50]. In the case
of the SKBR3 cell line, the path to breast cancer is particularly tightly constrained,
compared to the other cell lines we studied (Section 5.2.2), as there is only one
optimal order for these mutations to emerge.
Apoptosis remains lower in the model if p53 mutates early. This is as expected
if we assume that the order of mutations is more strongly constrained by negative
selection, in our model due to apoptosis, than positive selection by proliferation. This
contradicts some models of tumour development in colorectal [26] and pancreatic
cancer [37] but is consistent with experimental data for breast cancer [69, 56, 47]
where p53 is often mutated early, as well as other cancers [14].
ErbB2 (a.k.a HER2) has a more contextual effect in the model, with it increasing
apoptosis if it is the first mutation, but offering some protection from the downsides
of c-myc activation, through the PI3K pathway, if mutated after c-myc and p53. It
has been observed that when Ras, which is one of the key effectors of ErbB2 driven
signalling, is mutated alone, it is a less effective driver of tumourigenesis than when
it is combined with a mutation in c-myc, and vice-versa [42]. This is consistent with
the model prediction in that a mutation in ErbB2, which will activate Ras, raises
apoptosis, and so is detrimental to the cancer, when it mutates before c-myc (top left
edge in Fig. 5b), but is beneficial by lowering apoptosis when it mutates after c-myc
and p53 (bottom right edge in Fig. 5b), and so recapitulates this cooperation. Such
contextual behaviour will be important to map out as it will be a determinant of
what mutations are selected for in response to therapy. Similarly, if ErbB2 mutation
is beneficial or detrimental at different stages of tumour evolution, this suggests
that the order of mutation might influence whether a ErbB2 mutation is acquired at
all. Here we restrict ourselves to considering combinations of oncogenes which are
observed in one cell line, but this could be explored by considering together many
possible oncogenes, and seeing whether ErbB2 mutations are likely to be selected
for or against at different points, and whether this leads to diverging paths to cancer.
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Proliferation is a weaker constraint for this cell line with different paths offering
similar increases. Mutations which lead to high proliferation triggering higher apop-
tosis due to the coupling of the cell cycle to tumour suppression via p53, until this is
mitigated by other mutations (Fig. 5a).
5.2.2 Acquisition of mutations is constrained to varying degrees
While there is one optimal order in which the mutations exhibited by the SKBR3 cell
line can be acquired, this is not true for other sets of mutations observed in breast
cancer cell lines. For example, SUM159PT [28] (Fig. 6) shows 2 equally optimal















































































(b) The effect of mutations found in the SKBR3 cell line on
apoptosis.
Fig. 5: How proliferation and apoptosis change as a tumour acquires the mutations
seen in the SKBR3 cell line. The colour of the vertices corresponds to the level
of proliferation (blue) and apoptosis (red). Edge colour and label corresponds to
the mutation applied at each step, moving from top (healthy cell) to bottom (all
mutations). Act. means that a node has been set to maximum activity, Inact. means
a node has been set to 0 activity.








































(a) The effect of mutations found in the
SUM159PT cell line on apoptosis shows






































(b) The effect of mutations found in the
BT549 cell line on apoptosis show the or-
der can vary more compared to SUM159PT,
despite both being triple-negative cell lines.
Fig. 6: Comparison of degree of constraint by apoptosis in different cell lines with
an equal number of total mutations. (Left) The effect of mutations found in the
SUM159PT cell line on apoptosis shows more flexibility than SKBR3 cell line.
(Right) The effect of mutations found in the BT549 cell line on apoptosis show how
the order is more flexible compared to SUM159PT, despite both being triple-negative
cell lines.
such variance in the degree of constraint, even for phenotypically similar cell lines,
implies some flexibility in the acquisition of mutations, but with underlying patterns.
5.2.3 Difference in constraints from proliferation and apoptosis
While activation of tumour suppressormechanisms places a strong negative selection
pressure on tumour evolution, theremust also be selection for increased proliferation.
Strong constraints on oncogenes by apoptosis favour lineages in which c-myc, ErbB1
and ErbB2 mutate late. In the case of BT20 [43] however, there are many paths to
cancer which are unconstrained by apoptosis (Fig. 7b). Nevertheless, there are still
only a few paths which can be taken to maximise proliferation while also avoiding
apoptosis (Fig. 7a).
However, the path selected for may change as during growth different phenotypes
will be the limiting factor. In early stages, many mutations are often acquired by
a small number of cells, implying avoidance of tumour suppression mechanisms
is a prerequisite to the acquisition of proliferative mutations. Once escape from
safeguards is achieved, then rapid growth can and does occur [63, 61]. As the tumour
develops, other traits may take priority over such rapid growth, such as angiogenesis
to support the tumour. As competition for space becomes a factor, higher apoptosis
enabling a rapid turnover of cells may become tolerated.
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(a) The effect of mutations found in the BT20 cell line on prolif-
eration.
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(b) The effect of mutations found in the BT20 cell line on apop-
tosis.
Fig. 7: Comparison of the role played in restriction of order of mutations in the BT20
cell line by proliferation vs apoptosis. There are only two attractors of the model
which maximises possible proliferation for this cell line after 3 mutations, without
apoptosis, out of 10 possible attractors at this stage of evolution. This means there are
only 4 of a possible 21 minimal apoptosis paths that lead to maximum proliferative
benefit.
5.2.4 Cell lines show redundancy in mutations
We would expect the optimum state to emerge only with the full complement of
mutations for each cell line. This is true in the case of SKBR3, where proliferation is
maximised and apoptosisminimised only in the final combination of all themutations
observed in the cell line which apply to our model. However, this is not true for all
cell lines, for example BT20 (Fig. 7) gains no further benefit from mutation of p16
and p14ARF if p53 has been inactivated. Nevertheless, while the full path is not
selected for, neither is it selected against by apoptosis. This implies that this is partly
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a reflection of benefits not accounted for in our model.We only consider proliferation
and apoptosis, but a cancer must also acquire other traits in order to be successful
enough to be a candidate for a cell line. For example, the impact of our mutations on
invasiveness [68], differentiation [65], angiogenesis [7], and immune response [21]
will also exert selective pressures. However, these can be taken into account with
further refinements to the models input into this method. It is also likely that the
constraints of a cell line in vitro are different to those of a cancer in vivo, which may
require extra mutation that a cancer would not benefit from.
Conversely, there may be variation within the cell line, and cells may need only
a subset of all the mutations attributed to a cell line in order to be successful. If
there are multiple viable endpoints within the set of possible mutations, then this
method has the potential to predict which early mutations results in the choice of
the final combination of mutations. Similarly, it has been observed that the same
combination of mutations may result in different phenotypes, dependent upon the
order in which they were acquired [49, 59]. We did not observe this in the case of our
ER-negative breast cancer model, but the method is capable of finding such cases, as
the attractors under a combination of mutations depend upon the initial states, which
in turn depends upon the order of the previous mutations.
In these cases, the model could allow the use of early mutations as prognostic
biomarkers. This could allow prediction of the future evolution of a tumour from
early mutations and planning of therapy to account for this, perhaps to influence this
evolution, as discussed by Basanta et al. [6].
6 Future Work
Our newmethod to explore the constraints on and effects of the order of mutations in
the emergence of cancer could be extended to consider more phenotypes. However,
this requires further assumptions about how to balance the priorities of a tumour, for
example, how important is invasiveness to successful tumourigenesis compared to
proliferation at different stages. Our breast cancer model also currently focuses on
mutations which disrupt growth signalling in a cell-autonomous manner. External
signals factors can be included in the network as variables just as genes and proteins,
and so future models could explore the contribution of non-cell autonomous disrup-
tion to such signalling, and the spatial factors of cancer initiation, as reviewed in the
case of colorectal cancer by van den Brink et al [10].
Our method assumes that all cells start on a level playing field in the same healthy
state. However, even in healthy tissue there is an accumulation of neutral mutations
[45], and so a wide variety of starting points exist. Similarly, while it is true that
the vast majority of tumours will share a single founder cell, the landscape as the
system transitions from a pre-malignant lesion to an established cancer, as described
by Hanahan and Weinberg [34] will likely display neutral or only weakly selected
mutations, resulting in a diverse and branching system of sub-clones. In order to
explore this more fully, more diverse initial states can be considered, as well as
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investigation of population effects and the effect of competition and cooperation
between clones, with implications for early detection and treatment of cancer. We
also currently use the method to reconstruct the history of known tumours, but it
could also be used to predict how a larger set of mutations interacts.
A bottleneck in our methodology is the expansion of the 2M mutated models.
While we have not found this to be a problem with models of the scale we have
considered so far, this step will become computationally expensive when considering
a large number of mutated genes. A promising approach to deal with this limitation
is to consider an extension of qualitative networks which have explicit support
for dynamic modifications to target functions, akin to switching gene regulatory
networks [57]. In principle this would allow us to consider all mutated models
symbolically, in one step.
Analysis of the results will similarly become more complex as the number of
mutations increases, and also if more cellular behaviours than proliferation and
apoptosis are considered. As the number of combinations of mutations, M , increases,
the number of paths between them increases as M!, therefore finding the best paths
manually becomes infeasible. In the future it will be necessary automate the finding
of optimal paths based on scoring of the level of the different phenotypes the cancer
passes through, for example penalising those orderings of mutations which pass
through states with high apoptosis.
We currently assume that all mutations occur as single events, and with sufficient
time for the system to find an attractor between mutations. Relaxing this assumption
may be necessary in later stages of the cancer as chromosomal instability increases,
or in the case of mass chromosomal rearrangement events such as chromothripsis
[48, 20], chromoplexy [5] or kataegis [22].
Finally, while our model broadly agrees with the existing literature on the order of
mutations in breast cancer, further experimental testing of our predictions is possible.
The evolution of tumours has been studied in organoid systems, which more closely
model the conditions a developing cancer would face in vivo, [51]. Alternatively,
individual mutations can now be applied sequentially using emerging techniques
such as CRISPR-Cas9 [53]. This would allow experiments guided by our model to
closely recapitulate the early stages of tumour evolution.
7 Conclusions
We present a new method to find how behaviours such as proliferation and apop-
tosis constrain the order in which mutations are acquired during the emergence of
cancer. This required the use of binary decision diagrams, which allow the efficient
exploration of all possible attractors in qualitative networks, from any set of initial
states, simulated both synchronously and asynchronously. Further, we demonstrate
in a model of ER-negative breast cancer that different paths to cancer have varying
degrees of constraint placed upon them by apoptosis and proliferation. c-myc places
an especially strong bound on the paths that can be taken to tumourigenesis, while
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this order depends on the context of other mutations, such as ErbB2. Our study
could be expanded to provide a biological explanation, and be used as the basis for
prediction of patterns in tumour evolution.
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